Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 267

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 267
---
 or occurrence of an        
 IPO, the 2020 Notes principal and accrued interest will be automatically converted into 609,887 
 Ordinary Shares based on a pre money valuation of $5,150. In addition, upon conversion of       
 the CLAs to Ordinary Shares the Company will issue additional 553,640 Ordinary Shares to        
 the Participating Lenders which presents the additional amount provided by Participating        
 Lenders, the applicable accrued interest and the amount of $340 as a risk premium. As of        
 December 31, 2024, the Company received proceeds of $450 proceeds from the issuance of the      
 additional 2020 Notes. On March 31, 2025, the Company and the lenders signed an amendment       
 to the loan agreement to extend the maturity date until the earlier of August 31, 2025 or       
 consummation of an IPO.                                                                         |

The Company estimates the fair value
of the 2020 Notes using the Probability-Weighted Expected Return Method (PWERM). For years ended December 31, 2024 and 2023, the Company
recorded an income/ (expense) of $3,483 and $(2,019) for the revaluation of such 2020 Notes, within financial expense, net in the statements
of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of 2020 Notes outstanding are as follows:

|                  |     |   | December 31, 
         2024 |   |     |   | December 31, 
         2023 |   |
|:-----------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |        1,350 |   |     | $ |          900 |   |
| Discount rate    |     |   |           30 | % |     |   |         30.0 | % |
| Term (years)     |     |   |         0.40 |   |     |   |         0.25 |   |
| Fair value       |     | $ |        4,372 |   |     | $ |        7,405 |   |

<div align='center'>F-17</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and